These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 20062917)

  • 1. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
    Kretz CA; Cuddy KK; Stafford AR; Fredenburgh JC; Roberts R; Weitz JI
    Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
    Kretz CA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2006 Dec; 281(49):37477-85. PubMed ID: 17046833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
    Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M
    Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
    Bompiani KM; Monroe DM; Church FC; Sullenger BA
    J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
    Müller J; Freitag D; Mayer G; Pötzsch B
    J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
    Lindhout T; Blezer R; Hemker HC
    Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
    Tanaka KA; Szlam F; Rusconi CP; Levy JH
    Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase.
    Bukys MA; Orban T; Kim PY; Nesheim ME; Kalafatis M
    Thromb Haemost; 2008 Mar; 99(3):511-22. PubMed ID: 18327399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
    Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
    Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
    Monteiro RQ; Zingali RB
    Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of prothrombin activation by bothrojaracin, a C-type lectin from Bothrops jararaca venom.
    Monteiro RQ; Zingali RB
    Arch Biochem Biophys; 2000 Oct; 382(1):123-8. PubMed ID: 11051105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleavage requirements of factor V in tissue-factor induced thrombin generation.
    Thorelli E; Kaufman RJ; Dahlbäck B
    Thromb Haemost; 1998 Jul; 80(1):92-8. PubMed ID: 9684792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway.
    Lovely RS; Boshkov LK; Marzec UM; Hanson SR; Farrell DH
    Br J Haematol; 2007 Nov; 139(3):494-503. PubMed ID: 17910639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J; Mattsson C; Inghardt T; Elg M
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
    De Smedt E; Wagenvoord R; Coen Hemker H
    Thromb Haemost; 2009 Jan; 101(1):165-70. PubMed ID: 19132204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.